Why did ATX.AX stock spike so sharply today?

No ASX announcement matched the volume surge; the move likely reflects speculative flows or a block trade. Volume reached 55,821,757 against an average of 633,537, driving the **A$0.235** close and 113.64% gain.

What is Meyka AI's view on ATX.AX stock performance?

Meyka AI rates ATX.AX with a score out of 100 at 67.58 (Grade B, HOLD). The rating weighs sector comparison, financial growth, metrics and forecasts and is informational, not investment advice.

What are realistic price targets and the forecast for ATX.AX stock?

Scenario targets: conservative **A$0.12**, base **A$0.22**, bull **A$0.40**. Meyka AI's forecast model projects **A$0.175** in 12 months and **A$0.248** in 3 years. Forecasts are projections and not guarantees.

What are the main risks for ATX.AX stock investors?

Major risks include negative clinical outcomes, licensing failure, and dilution from capital raises. Amplia has 513,071,629 shares outstanding and limited revenue, so trial results will materially affect valuation.

AU Stocks

ATX.AX stock up 113.64% to A$0.235 on ASX 23 Mar 2026: catalyst eyed

ByHuzaifa Zahoor March 23, 2026March 23, 2026

The stock moved sharply today: Amplia Therapeutics Limited (ATX.AX stock) rose 113.64% to A$0.235 on the ASX as volume surged to 55,821,757 shares. This high-volume mover outpaced its 50-day average of A$0.13055 and average daily volume of 633,537. The jump came with no confirmed ASX announcement in public feeds, suggesting heavy speculative trading or a large block trade. We examine what the volume spike means for valuation, technicals and the near-term outlook on the ASX in Australia